vs
Side-by-side financial comparison of LCNB CORP (LCNB) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $23.9M, roughly 1.2× LCNB CORP). LCNB CORP runs the higher net margin — 23.7% vs -147.1%, a 170.8% gap on every dollar of revenue. On growth, LCNB CORP posted the faster year-over-year revenue change (5.1% vs -67.6%).
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
LCNB vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.9M | $28.1M |
| Net Profit | $5.7M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 29.2% | -147.6% |
| Net Margin | 23.7% | -147.1% |
| Revenue YoY | 5.1% | -67.6% |
| Net Profit YoY | -7.6% | -182.8% |
| EPS (diluted) | $0.40 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.9M | $28.1M | ||
| Q3 25 | $23.8M | $32.5M | ||
| Q2 25 | $22.8M | $15.7M | ||
| Q1 25 | $21.5M | $8.0M | ||
| Q4 24 | $22.7M | $86.6M | ||
| Q3 24 | $21.4M | $2.1M | ||
| Q2 24 | $19.3M | $500.0K | ||
| Q1 24 | $17.8M | $0 |
| Q4 25 | $5.7M | $-41.3M | ||
| Q3 25 | $6.9M | $-51.2M | ||
| Q2 25 | $5.9M | $-44.9M | ||
| Q1 25 | $4.6M | $-33.9M | ||
| Q4 24 | $6.1M | $49.9M | ||
| Q3 24 | $4.5M | $-19.1M | ||
| Q2 24 | $925.0K | $-12.5M | ||
| Q1 24 | $1.9M | $-10.3M |
| Q4 25 | 29.2% | -147.6% | ||
| Q3 25 | 35.6% | -163.7% | ||
| Q2 25 | 31.6% | -302.9% | ||
| Q1 25 | 25.6% | -466.3% | ||
| Q4 24 | 32.9% | 54.5% | ||
| Q3 24 | 24.9% | -1051.6% | ||
| Q2 24 | 4.9% | -3068.0% | ||
| Q1 24 | 12.5% | — |
| Q4 25 | 23.7% | -147.1% | ||
| Q3 25 | 29.1% | -157.4% | ||
| Q2 25 | 26.0% | -285.6% | ||
| Q1 25 | 21.4% | -425.7% | ||
| Q4 24 | 27.0% | 57.7% | ||
| Q3 24 | 21.2% | -925.0% | ||
| Q2 24 | 4.8% | -2503.2% | ||
| Q1 24 | 10.7% | — |
| Q4 25 | $0.40 | $-0.41 | ||
| Q3 25 | $0.49 | $-0.52 | ||
| Q2 25 | $0.41 | $-0.46 | ||
| Q1 25 | $0.33 | $-0.35 | ||
| Q4 24 | $0.44 | $0.52 | ||
| Q3 24 | $0.31 | $-0.20 | ||
| Q2 24 | $0.07 | $-0.13 | ||
| Q1 24 | $0.15 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.6M | $245.0M |
| Total DebtLower is stronger | $104.4M | $96.4M |
| Stockholders' EquityBook value | $273.9M | $114.3M |
| Total Assets | $2.2B | $327.7M |
| Debt / EquityLower = less leverage | 0.38× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.6M | $245.0M | ||
| Q3 25 | $35.9M | $288.2M | ||
| Q2 25 | $49.8M | $240.1M | ||
| Q1 25 | $37.7M | $275.7M | ||
| Q4 24 | $35.7M | $314.0M | ||
| Q3 24 | $39.4M | $204.6M | ||
| Q2 24 | $34.9M | $218.7M | ||
| Q1 24 | $33.0M | $223.6M |
| Q4 25 | $104.4M | $96.4M | ||
| Q3 25 | $104.7M | $96.2M | ||
| Q2 25 | $105.0M | — | ||
| Q1 25 | $104.6M | — | ||
| Q4 24 | $155.2M | $0 | ||
| Q3 24 | $155.7M | — | ||
| Q2 24 | $162.2M | — | ||
| Q1 24 | $162.6M | — |
| Q4 25 | $273.9M | $114.3M | ||
| Q3 25 | $269.9M | $147.7M | ||
| Q2 25 | $263.5M | $192.3M | ||
| Q1 25 | $258.7M | $229.0M | ||
| Q4 24 | $253.0M | $256.8M | ||
| Q3 24 | $253.2M | $201.0M | ||
| Q2 24 | $245.2M | $215.2M | ||
| Q1 24 | $233.7M | $223.9M |
| Q4 25 | $2.2B | $327.7M | ||
| Q3 25 | $2.2B | $372.8M | ||
| Q2 25 | $2.3B | $313.5M | ||
| Q1 25 | $2.3B | $327.3M | ||
| Q4 24 | $2.3B | $351.2M | ||
| Q3 24 | $2.3B | $217.6M | ||
| Q2 24 | $2.4B | $222.0M | ||
| Q1 24 | $2.3B | $227.6M |
| Q4 25 | 0.38× | 0.84× | ||
| Q3 25 | 0.39× | 0.65× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.61× | 0.00× | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.4M | $-43.5M |
| Free Cash FlowOCF − Capex | $33.4M | — |
| FCF MarginFCF / Revenue | 140.2% | — |
| Capex IntensityCapex / Revenue | 4.0% | 0.0% |
| Cash ConversionOCF / Net Profit | 6.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | $54.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.4M | $-43.5M | ||
| Q3 25 | $14.0M | $-47.0M | ||
| Q2 25 | $5.5M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.7M | ||
| Q4 24 | $93.2M | $42.0M | ||
| Q3 24 | $11.9M | $-14.5M | ||
| Q2 24 | $54.9M | $-7.3M | ||
| Q1 24 | $-11.9M | $-6.7M |
| Q4 25 | $33.4M | — | ||
| Q3 25 | $13.7M | $-47.2M | ||
| Q2 25 | $5.2M | $-39.6M | ||
| Q1 25 | $2.1M | $-40.8M | ||
| Q4 24 | $89.4M | $41.7M | ||
| Q3 24 | $10.5M | $-14.6M | ||
| Q2 24 | $53.8M | $-7.3M | ||
| Q1 24 | $-12.8M | $-6.8M |
| Q4 25 | 140.2% | — | ||
| Q3 25 | 57.4% | -145.4% | ||
| Q2 25 | 23.0% | -252.2% | ||
| Q1 25 | 10.0% | -512.1% | ||
| Q4 24 | 394.0% | 48.2% | ||
| Q3 24 | 49.0% | -706.3% | ||
| Q2 24 | 278.6% | -1463.4% | ||
| Q1 24 | -71.8% | — |
| Q4 25 | 4.0% | 0.0% | ||
| Q3 25 | 1.3% | 0.6% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 0.3% | 1.1% | ||
| Q4 24 | 16.7% | 0.3% | ||
| Q3 24 | 6.7% | 6.8% | ||
| Q2 24 | 5.9% | 7.6% | ||
| Q1 24 | 4.8% | — |
| Q4 25 | 6.08× | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 15.23× | 0.84× | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 59.35× | — | ||
| Q1 24 | -6.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LCNB
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
